Dermira (DERM) versus Microbot Medical (NASDAQ:MBOT) Head to Head Comparison

Microbot Medical (NASDAQ: MBOT) and Dermira (NASDAQ:DERM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.


This table compares Microbot Medical and Dermira’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Microbot Medical N/A -157.27% -140.17%
Dermira -6,678.29% -62.07% -29.13%

Earnings & Valuation

This table compares Microbot Medical and Dermira’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Microbot Medical $120,000.00 263.12 -$9.66 million ($0.69) -1.19
Dermira $4.54 million 94.51 -$303.26 million ($7.37) -1.39

Microbot Medical has higher earnings, but lower revenue than Dermira. Dermira is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Microbot Medical has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500. Comparatively, Dermira has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Microbot Medical and Dermira, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Microbot Medical 0 0 1 0 3.00
Dermira 2 2 5 0 2.33

Microbot Medical presently has a consensus target price of $1.75, suggesting a potential upside of 113.94%. Dermira has a consensus target price of $32.71, suggesting a potential upside of 218.85%. Given Dermira’s higher probable upside, analysts plainly believe Dermira is more favorable than Microbot Medical.

Institutional and Insider Ownership

5.1% of Microbot Medical shares are owned by institutional investors. Comparatively, 94.9% of Dermira shares are owned by institutional investors. 31.8% of Microbot Medical shares are owned by insiders. Comparatively, 13.3% of Dermira shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Microbot Medical Company Profile

Microbot Medical Inc., formerly StemCells, Inc., is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures. Its ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. The Microbot SCS device is a robotic system designed as the ventricular catheter portion of a cerebrospinal fluid (CSF) shunt system. The Company’s TipCAT is an endoscope that provides see and treat capabilities within tubular lumens in the human body, such as the colon, blood vessels and the urinary tract.

Dermira Company Profile

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with's FREE daily email newsletter.

Leave a Reply